Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Indiana University
Modality
Other
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06508827CT.gov Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Iron Deficiency Anemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Iron Dextran (this asset) | Indiana University | P2 | CCC · 53 |
| Ferric Cation | Fundación para la Investigación del Hospital Clínico de Valencia | P4 | A |
| Iron Isomaltoside | China-Japan Friendship Hospital | P4 | BBB |
| Iron(Ii) Sulphate (1:1), Heptahydrate | Linda Malan | P4 | BBB |
| Sodium Ferric Gluconate | Watson Pharmaceuticals | P4 | BBB |
| Iron | Cairo University | P4 | BB |
| Iron Hydroxide Polymaltose | Kaplan Medical Center | P3 | BB |
| Ferumoxytol | Auerbach Hematology Oncology Associates P C | P2 | B |
| KER047 | Keros Therapeutics, Inc. | P2 | CCC |
+5 more in the Iron Deficiency Anemia cohort
Other indications for Iron Dextran
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Melanoma | — | P2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Iron Dextran in Iron Deficiency Anemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/iron-dextran-iron-deficiency-anemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →